US Pharma Cloud Services Market Grows with Rising Adoption of Cloud Computing Technologies

Growing adoption of cloud-based computing in pharma is driven by advantages like enhanced collaboration, data security, agility, and scalability, which drive the growth of the market.

What are Pharma Cloud Services?

Cloud computing allows the healthcare community to revolutionise rapidly, manage changes smoothly, and deliver novel medicines to the marketplace. Cloud-based infrastructure provides secure storage for sizable and sensitive data. It supports data security, integrity, and compliance with controlling entities. Cloud-based environments are also secure when it comes to control over and access to information. Reputable cloud facility providers provide continuous security monitoring and incident response, and they rapidly identify security challenges and apply patches. Cloud is at the forefront of the technologies leading digital transformation in the healthcare industry.

Market Growth

The global pharma cloud services market size was estimated at USD 10.86 billion in 2025 and is predicted to increase from USD 12.47 billion in 2026 to approximately USD 43.18 billion by 2035, expanding at a CAGR of 14.8% from 2026 to 2035.

Recent Advancements in Hybrid and Multi-Cloud Technology:

Recent advancements in hybrid and multi-cloud environments are intended to be more interoperable, enabling seamless integration among cloud services and on-premises systems, which is significant for maintaining operational continuity and government compliance. Multi-cloud strategies enable pharma organizations to optimize workloads by choosing the standard provider for every specific task, whether it’s for R&D, data analytics, or supply chain management, based on expenses, performance, or particular compliance capabilities. Hybrid and multi-cloud strategies offer pharmaceutical organizations the flexibility to revolutionize and scale operations while preserving strict control over sensitive data and significant applications.

Market Segmentation Overview

• By service type, the SaaS (software as a service) segment contributed the largest U.S. pharma cloud services market share of 52% in 2025, as medical care SaaS is a cloud-based software solution which used by medical care providers and other organizations to offer medical-related solutions. Medical SaaS removes inefficiencies in billing, scheduling, and data management, freeing up time for medical care professionals.
• By deployment model, the public cloud segment contributed the largest market share of 30%, as public clouds provide virtually unlimited scalability. Consumers quickly increase or decrease resource usage based on demand without worrying about running out of volume. It deploys services closer to end users from public cloud data centers globally. As public clouds are managed by a third party, it is an easy and hassle-free technology.
• By application, the clinical trials segment contributed the largest U.S. pharma cloud services market share of 34%, as cloud computing is transforming clinical trials by integrating data management, decreasing trial expenses, and limiting the timelines. It allows real-time data sharing across multiple sites, enhancing collaboration and decision-making. Cloud platforms offer flexible resources for computationally intensive simulations, high-throughput virtual screening, or large-scale medical data analysis.
• By end user, the pharmaceutical companies segment contributed the largest market share of 42%, as it offers support for pharma's marketing activities. With the strength of cloud computing, pharmaceutical organizations accelerate their digital transformation and deliver advanced patient outcomes. Cloud computing offers immense, accessible computing power for modelling and simulation. Cloud platforms enable decentralised clinical trials (DCTs), allowing remote patient monitoring services.

Top Companies in the U.S. Pharma Cloud Services Market

The top four companies in this market dominate the U.S. pharma cloud services market. Meanwhile, Ashland Inc, it has an inclusive portfolio of cellulose ethers, polymers, and specialty excipients for controlled-release preparations. Dow Chemical is the leading provider of high-quality raw materials and functional polymers for large-scale manufacturing. Lubrizol Corporation offers specialty materials focusing on drug delivery systems. SPI Pharma significantly focuses on specialty excipients, involving antacids and orally disintegrating drug delivery technology.

Segments Covered in the Report

By Service Type

• SaaS (Software as a Service)
  • Clinical Data Management
  • Regulatory Compliance Software
  • Drug Safety/Pharmacovigilance
  • ERP & Supply Chain
• PaaS (Platform as a Service)
  • Application Development Platforms
  • Integration Platforms
• IaaS (Infrastructure as a Service)
  • Storage Services
  • Compute Services
  • Disaster Recovery

By Deployment Model

• Public Cloud
• Private Cloud
• Hybrid Cloud

By Application

• Clinical Trials
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Drug Discovery
  • Genomics & Proteomics
  • AI-based Drug Modeling
• Manufacturing & Supply Chain
  • Production Monitoring
  • Logistics & Distribution
• Regulatory & Compliance
• Sales & Marketing

By End User

• Pharmaceutical Companies
  • Large Pharma
  • Small & Mid-sized Pharma
• Biotechnology Companies
• CROs (Contract Research Organizations)
• CMOs/CDMOs
• Others (Regulatory bodies, Research Institutes)